Tennessee is moving forward with clinical trials of ibogaine, a Schedule I psychedelic drug that has been fast-tracked for research under a federal executive order signed by President Donald Trump. The state joins Texas and Arizona, as well as a handful of other states currently considering similar legislation, in studying the drug.
Tennessee lawmakers passed the HOPE Act (Helping Open Pathways to Effective Treatment) a week after the federal action, specifically aimed at expanding treatment options for veterans facing mental health challenges. The legislation enables Tennessee to participate in FDA-approved clinical trials of ibogaine, with university researchers closely monitoring patients receiving the drug. Ibogaine, which is derived from plants native to West Africa and classified in the same Schedule I category as LSD, is believed to help treat opioid addiction, depression, and PTSD by altering brain function.
Advocates of ibogaine research point to its potential. Bryan Hubbard of Americans for Ibogaine stated that “ibogaine has the potential, over the course of perhaps two to three treatments over an individual’s lifetime, to physiologically resolve opioid addiction even among those who have been dependent for decades.” A retired Navy SEAL, Alex West, testified to state lawmakers that ibogaine treatment saved his life after years of depression and substance abuse linked to combat. He reported being “six years sober from alcohol and no longer on any psychotropic medication, down from five,” noting he had previously traveled outside the United States to access the drug.
Currently, no traditional psychedelic drugs are approved for medical treatment in the United States. If ibogaine is approved through clinical trials, it would be the first. State Sen. Page Walley, a Republican from Savannah who sponsored the bill, stated that existing tools for treating mental health conditions “just aren’t well enough or fast enough.” Tennessee officials plan to begin accepting proposals from universities interested in conducting the trials later this year.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://newschannel9.com/news/local/tn-clears-way-for-clinical-trials-for-ibogaine-same-drug-classification-as-lsd